The Foundation for the NIH investigates metabolic disease links
The Foundation for the NIH, in collaboration with the National Institute of Diabetes and Digestive and Kidney Diseases, announced a new partnership to investigate links across serious common diseases.
To better understand the molecular basis and discover disease targets and biomarkers, the Accelerating Medicines Partnership for Common Metabolic Diseases will focus on clarifying the links between obesity, type 2 diabetes, prediabetes, cardiovascular diseases, kidney disease and liver diseases. This partnership aims to build on scientific advances and analytics tools while adding new information to develop new tools that will be made available to the entire scientific community.
“Metabolic diseases affect one-third of the global population, leading to a high public health and medical burden. So far, drug development has concentrated on treating individual diseases, but growing evidence shows that the presence of one metabolic disease substantially increases the risk to develop others,” Maria C. Freire, PhD, president and executive director of the Foundation for the NIH, said in a press release, “Many patients experience several such diseases throughout their lifetime, strongly suggesting common underlying causality. Accelerating Medicines Partnership for Common Metabolic Diseases will help sort out these links.”
Amgen, Eli Lilly and Company, Novo Nordisk, Pfizer and the National Institute of Diabetes and Digestive and Kidney Diseases will invest $57 million over the next 5 years to support this project.